Placebos exist in clinical trials for one fundamental reason: without them, there’s no reliable way to know whether a treatment actually works. A sugar pill or saline injection serves as the scientific baseline, separating real drug effects from the body’s own powerful response to simply believing it’s being treated. This distinction sounds simple, but the biology and statistics behind it reveal why placebos remain essential to modern medicine.
Establishing a True Baseline
When someone takes a new medication and feels better, several things could explain the improvement. The disease might have run its natural course. Symptoms could have fluctuated on their own. The person might unconsciously report feeling better because they expect to. Or the drug might genuinely work. A placebo group captures all of those non-drug factors, so researchers can subtract them out and isolate what the treatment itself is doing.
This is the same logic behind a control experiment in any science. If you’re testing whether a fertilizer helps plants grow, you need identical plants that didn’t receive the fertilizer. In medicine, the “unfertilized plant” is a group of patients who go through the exact same experience, including clinic visits, pill-taking routines, and medical monitoring, but receive an inert substance instead of the active drug. Any difference in outcomes between the two groups can then be attributed to the drug with much greater confidence.
The Placebo Effect Is Real Biology
The placebo effect isn’t imaginary. When people believe they’re receiving treatment, their brains respond with measurable physical changes. Researchers have now identified a specific neural circuit, running from a region in the front of the brain through a relay station called the pontine nucleus to the cerebellum, that actively reduces pain perception in people given placebos. Activating these neurons through direct stimulation produces pain relief even without any placebo conditioning, confirming this is a genuine biological pathway.
The brain also releases its own chemical toolkit during a placebo response. Natural opioids, cannabinoids, and dopamine all play roles. The dopamine pathways involved in reward anticipation are particularly active in conditions like Parkinson’s disease, where placebo responses can be dramatic. The brain can even send signals down the spinal cord to dampen pain intensity using these self-produced chemicals.
This is precisely why placebos are so necessary in trials. If 30% of patients improve on a sugar pill because their brains are generating real neurochemical changes, a drug needs to beat that 30% to prove it offers something beyond what expectation alone provides. Without a placebo group, a drug that helps 35% of patients looks effective, when in reality its added benefit is only 5 percentage points.
How Placebos Prevent Bias
Placebos make blinding possible. In a double-blind trial, neither patients nor researchers know who is getting the real treatment. This matters enormously, because unblinded participants report exaggerated improvements by an average of 0.56 standard deviations compared to blinded participants. For invasive procedures, the gap is even wider.
The bias isn’t limited to patients. When outcome assessors know which group a patient belongs to, their evaluations skew as well. Three separate meta-analyses found that unblinded assessors exaggerated results by 27% for time-based outcomes, 36% for yes-or-no outcomes, and 68% for outcomes measured on a scale. These aren’t subtle distortions. They’re large enough to make an ineffective drug appear to work.
Without a placebo that looks, tastes, and feels identical to the real treatment, blinding falls apart. Patients figure out which group they’re in, start reporting differently, and the data becomes unreliable. Unblinded trials also see significantly higher dropout rates in control groups, further distorting results.
The Nocebo Effect Complicates Things Further
Placebos also reveal something unexpected: people taking sugar pills report side effects that mirror the real drug’s known problems. This phenomenon, called the nocebo effect, shows up consistently across therapeutic areas. In anti-migraine trials, patients given placebos in anticonvulsant studies reported anorexia, memory difficulties, and tingling, all side effects listed for the actual anticonvulsant drugs. Patients in the placebo arms of separate triptan trials reported different side effects, matching the triptan profile instead.
A meta-analysis of 143 antidepressant trials found that placebo recipients in older tricyclic antidepressant studies reported dry mouth at triple the rate (19.2% vs. 6.4%) and vision problems at nearly six times the rate (6.9% vs. 1.2%) compared to placebo recipients in newer SSRI studies. The pills were equally inert in both cases. The difference came from what patients were told to expect. In statin trials, 4% to 26% of patients in control groups actually stopped taking their placebo because of perceived side effects.
This data is only visible because a placebo group exists. Without one, every reported side effect gets attributed to the drug, inflating its apparent risk profile.
Placebos Beyond Pills
Placebo controls extend well beyond sugar pills. In surgical trials, researchers use “sham procedures” to test whether an operation’s benefits come from the surgery itself or from the experience of having surgery. In a landmark trial of arthroscopic knee surgery for osteoarthritis, patients in the control group received only a small skin incision under sedation. The surgeon requested the standard instruments and manipulated the knee as if performing the real procedure while splashing water to mimic the sound of lavage. The sham surgery group improved just as much as those who had the real operation.
Acupuncture trials use retractable needles that look and feel like standard treatment but don’t penetrate the skin. In studies of laser cardiac procedures, control patients are blindfolded and sedated while laser equipment is wheeled in and treatment is discussed normally, but no laser is actually fired. These elaborate controls exist because physical interventions can produce even stronger placebo effects than pills.
When Placebos Are Not Appropriate
Placebos aren’t always ethical. The Declaration of Helsinki, the international standard for medical research ethics, states that when an effective treatment already exists for a condition, using a placebo is only justified if withholding treatment won’t cause serious or irreversible harm. You can’t give a cancer patient a sugar pill when proven chemotherapy is available.
This principle has pushed many fields toward “active comparator” trials, where a new drug is tested against the current best treatment rather than against nothing. This design answers a different but equally important question: not “does this drug work?” but “does this drug work better than what we already have?” In inflammatory bowel disease, for example, the growing number of approved therapies has made placebo-only controls increasingly controversial, since patients in the placebo group may deteriorate while effective treatments exist.
The trade-off is scientific. Active comparator trials are harder to interpret because both groups are receiving something that works, making differences between them smaller and requiring larger patient populations to detect. Placebo-controlled trials produce cleaner, more definitive answers about whether a drug has any effect at all. Regulators and researchers weigh these considerations for every new study.
Placebo Run-In Periods
Some trials use a placebo run-in phase before the actual experiment begins. During this period, all enrolled patients receive a placebo for a set number of weeks. Those who improve substantially during this phase, the high placebo responders, are then excluded from the main trial. The goal is to enrich the study population with patients whose improvements are more likely to reflect a real drug response rather than a placebo response, making the trial more sensitive to detecting genuine treatment effects.
This approach is common in antidepressant research, where placebo response rates are notoriously high. The practice is debated, though, because it excludes treatment-seeking patients who might benefit from full participation in the trial, and its actual impact on study outcomes remains uncertain.